Gut microbiota and inflammatory bowel disease

Area of Science:

• Gastroenterology
• Microbiology
• Immunology

Background:

• The gut microbiome significantly influences inflammatory bowel disease (IBD) pathogenesis and symptoms.
• Antibiotics and probiotics are explored for their potential to modulate the gut flora in IBD.
• Current evidence for these interventions in IBD is evolving, with varying degrees of efficacy.

Purpose of the Study:

• To review the role of bacterial manipulation in IBD.
• To assess the efficacy of antibiotics and probiotics in managing IBD and its complications.
• To discuss future directions for therapeutic manipulation of the intestinal flora in IBD.

Main Methods:

• Review of existing clinical trials and studies on antibiotics and probiotics in IBD.
• Analysis of evidence for metronidazole, ciprofloxacin, probiotics, prebiotics, and synbiotics.
• Consideration of strain-specificity and limitations of probiotic efficacy.

Main Results:

• Metronidazole and ciprofloxacin show effectiveness in specific IBD conditions like Crohn's colitis and pouchitis.
• Probiotics offer modest benefits, with evidence for relapse prevention in pouchitis and ulcerative colitis.
• The efficacy of probiotics is strain-specific and depends on disease manifestation and duration of use.

Conclusions:

• Therapeutic manipulation of intestinal flora holds promise for IBD treatment.
• Large, controlled trials are necessary to establish widespread clinical acceptance.
• These strategies may complement traditional anti-inflammatory and immunosuppressive therapies for IBD.